{
    "nct_id": "NCT05355701",
    "official_title": "A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS",
    "inclusion_criteria": "* Diagnosis of advanced/metastatic solid tumor including primary brain tumor.\n* Qualifying BRAF alteration (V600 or non-V600 Class II/Class III BRAF alteration), in tumor tissue and/or blood (ie circulating tumor deoxyribonucleic acid [DNA], or ctDNA).\n* Disease progressed during/following last prior treatment and no satisfactory alternative treatment options (Part 1 and Part 2).\n* Tumor specific cohorts (melanoma, colorectal cancer) must have received specific prior approved therapies\nHealthy volunteers allowed\nMust have minimum age of 16 Years",
    "exclusion_criteria": "* Brain metastasis larger than 4 cm\n* Systemic anti-cancer therapy or small molecule therapeutics ongoing at the start of study treatment.\n* For participants who may get binimetinib on study, history or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)",
    "miscellaneous_criteria": "This study is seeking participants who meet the following eligibility criteria:"
}